AU2001292046A1 - Use of a ppar delta activator for treating inflammatory conditions - Google Patents

Use of a ppar delta activator for treating inflammatory conditions

Info

Publication number
AU2001292046A1
AU2001292046A1 AU2001292046A AU9204601A AU2001292046A1 AU 2001292046 A1 AU2001292046 A1 AU 2001292046A1 AU 2001292046 A AU2001292046 A AU 2001292046A AU 9204601 A AU9204601 A AU 9204601A AU 2001292046 A1 AU2001292046 A1 AU 2001292046A1
Authority
AU
Australia
Prior art keywords
treating inflammatory
inflammatory conditions
ppar delta
delta activator
activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292046A
Other languages
English (en)
Inventor
Kevin William Buchan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001292046A1 publication Critical patent/AU2001292046A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AU2001292046A 2000-10-05 2001-10-01 Use of a ppar delta activator for treating inflammatory conditions Abandoned AU2001292046A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0024361.8A GB0024361D0 (en) 2000-10-05 2000-10-05 Medicaments
GB0024361.8 2000-10-05
PCT/GB2001/004373 WO2002028434A2 (en) 2000-10-05 2001-10-01 Use of a ppar delta activator for treating inflammatory conditions

Publications (1)

Publication Number Publication Date
AU2001292046A1 true AU2001292046A1 (en) 2002-04-15

Family

ID=9900709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292046A Abandoned AU2001292046A1 (en) 2000-10-05 2001-10-01 Use of a ppar delta activator for treating inflammatory conditions

Country Status (9)

Country Link
US (1) US7084161B2 (https=)
EP (1) EP1324774B1 (https=)
JP (1) JP4106263B2 (https=)
AT (1) ATE318615T1 (https=)
AU (1) AU2001292046A1 (https=)
DE (1) DE60117584T2 (https=)
ES (1) ES2259675T3 (https=)
GB (1) GB0024361D0 (https=)
WO (1) WO2002028434A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070011A2 (en) * 2001-02-02 2002-09-12 Smithkline Beecham Corporation Treatment of ppar mediated diseases
WO2002100351A2 (en) * 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
BR0212512A (pt) 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
FR2836829B1 (fr) * 2002-03-11 2005-11-25 Bio Merieux Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
JP2007530703A (ja) * 2004-04-01 2007-11-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド Ｍｓおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
WO2006020830A2 (en) 2004-08-12 2006-02-23 Amgen Inc. Bisaryl-sulfonamides
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
BRPI0620468A2 (pt) 2005-12-22 2011-11-08 Transtech Pharma, Inc. ácidos fenóxi acéticos como ativadores de ppar delta
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
CA2687957C (en) * 2007-05-21 2014-11-25 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing ppar.delta. agonist
CN102724978A (zh) * 2009-08-14 2012-10-10 塞伦尼斯治疗公司 用于治疗或预防炎症或能量代谢/产生相关疾病的PPARδ配体的用途
KR102038866B1 (ko) * 2012-12-24 2019-10-31 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 항생제, 화상 및 창상 치료제, 당뇨성 족부궤양 치료제로서의 용도
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
CA2295930C (en) * 1997-07-24 2010-12-14 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical compositions having cholesterol-lowering effect
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
WO2002028434A3 (en) 2002-08-15
ES2259675T3 (es) 2006-10-16
US7084161B2 (en) 2006-08-01
DE60117584T2 (de) 2006-12-21
US20050131035A1 (en) 2005-06-16
GB0024361D0 (en) 2000-11-22
EP1324774A2 (en) 2003-07-09
JP4106263B2 (ja) 2008-06-25
ATE318615T1 (de) 2006-03-15
JP2004510750A (ja) 2004-04-08
WO2002028434A2 (en) 2002-04-11
EP1324774B1 (en) 2006-03-01
DE60117584D1 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
AU2001292046A1 (en) Use of a ppar delta activator for treating inflammatory conditions
NZ530772A (en) 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
ATE50256T1 (de) Hypoglycemische thiazolidinedione.
IL182647A0 (en) An oral preparation having improved bioavailability
PE20010406A1 (es) ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd
RU92004381A (ru) Производные 2-замещенного сахарина как ингибиторы протеолитических ферментов
EP1078923A3 (en) Process for the preparation of benzothiophene derivatives
PE20030326A1 (es) Derivados del acido indan acetico y su uso como agentes farmaceuticos, intermediarios y metodo de preparacion
MXPA02005604A (es) Aminobenzofenonas como inhibidores de il-1beta y tnf-alfa.
KR960041168A (ko) 베타-아드레날린 효능성 작용물질
AU2002215932A1 (en) Nitroderivatives as drugs for diseases having an inflammatory basis
ITRM20020016A0 (it) Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
AR037164A1 (es) Metodo de tratamiento.
MX2022013021A (es) Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.
DE60042161D1 (de) Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen
WO2002000611A8 (en) Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
CO4980892A1 (es) Nuevas formas seudopolimorficas del dihidrocloruro del acido 2-(2-(4-(bis(4-fluorofenil)metil)-1-piperazinil)etoxi)aceti- co
WO2004112783A1 (en) New use iv
AU2328784A (en) Thiazolidinedione derivatives
AU6435000A (en) Process for preparing 1-(6-methylpyridin-3-yl)-2-((4-(methylsulphonyl) phenyl) ethanone
NZ505994A (en) Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases
WO2004026930A3 (en) The method for reducing inflammation using sti-571 or its salt
NO974958D0 (no) Ny fremgangsmåte for fremstilling av (-)-trans-N-p-fluorbenzoylmetyl-4-(p-fluorfenyl)-3-[[3,4-(metylendioksy)-fenoksy]metyl]-piperidin
AU2002230023A1 (en) Salts of 3-4(4-(2-phenoxazin- or phenothiazin-10-yl)alkoxy)phenyl)-2-alkoxypropanoic acid derivatives with ppar activity for the treatment of hyperlipimedia and type ii diabetes
EP1403260A3 (en) Optically active epoxy compounds and processes for their production